Literature DB >> 23804561

An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice.

Na-Ri Shin1, June-Chul Lee, Hae-Youn Lee, Min-Soo Kim, Tae Woong Whon, Myung-Shik Lee, Jin-Woo Bae.   

Abstract

BACKGROUND: Recent evidence indicates that the composition of the gut microbiota contributes to the development of metabolic disorders by affecting the physiology and metabolism of the host. Metformin is one of the most widely prescribed type 2 diabetes (T2D) therapeutic agents.
OBJECTIVE: To determine whether the antidiabetic effect of metformin is related to alterations of intestinal microbial composition.
DESIGN: C57BL/6 mice, fed either a normal-chow diet or a high-fat diet (HFD), were treated with metformin for 6 weeks. The effect of metformin on the composition of the gut microbiota was assessed by analysing 16S rRNA gene sequences with 454 pyrosequencing. Adipose tissue inflammation was examined by flow cytometric analysis of the immune cells present in visceral adipose tissue (VAT).
RESULTS: Metformin treatment significantly improved the glycaemic profile of HFD-fed mice. HFD-fed mice treated with metformin showed a higher abundance of the mucin-degrading bacterium Akkermansia than HFD-fed control mice. In addition, the number of mucin-producing goblet cells was significantly increased by metformin treatment (p<0.0001). Oral administration of Akkermansia muciniphila to HFD-fed mice without metformin significantly enhanced glucose tolerance and attenuated adipose tissue inflammation by inducing Foxp3 regulatory T cells (Tregs) in the VAT.
CONCLUSIONS: Modulation of the gut microbiota (by an increase in the Akkermansia spp. population) may contribute to the antidiabetic effects of metformin, thereby providing a new mechanism for the therapeutic effect of metformin in patients with T2D. This suggests that pharmacological manipulation of the gut microbiota in favour of Akkermansia may be a potential treatment for T2D.

Entities:  

Keywords:  Intestinal Bacteria; Mucins; Obesity; Pharmacotherapy

Mesh:

Substances:

Year:  2013        PMID: 23804561     DOI: 10.1136/gutjnl-2012-303839

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  489 in total

1.  Deletion of intestinal epithelial insulin receptor attenuates high-fat diet-induced elevations in cholesterol and stem, enteroendocrine, and Paneth cell mRNAs.

Authors:  Sarah F Andres; M Agostina Santoro; Amanda T Mah; J Adeola Keku; Amy E Bortvedt; R Eric Blue; P Kay Lund
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-11-13       Impact factor: 4.052

Review 2.  Gut microbiome in health and disease: Linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases.

Authors:  Shivani Ghaisas; Joshua Maher; Anumantha Kanthasamy
Journal:  Pharmacol Ther       Date:  2015-11-26       Impact factor: 12.310

3.  Gut microbiota and intestinal FXR mediate the clinical benefits of metformin.

Authors:  Lulu Sun; Cen Xie; Guang Wang; Yue Wu; Qing Wu; Xuemei Wang; Jia Liu; Yangyang Deng; Jialin Xia; Bo Chen; Songyang Zhang; Chuyu Yun; Guan Lian; Xiujuan Zhang; Heng Zhang; William H Bisson; Jingmin Shi; Xiaoxia Gao; Pupu Ge; Cuihua Liu; Kristopher W Krausz; Robert G Nichols; Jingwei Cai; Bipin Rimal; Andrew D Patterson; Xian Wang; Frank J Gonzalez; Changtao Jiang
Journal:  Nat Med       Date:  2018-11-05       Impact factor: 53.440

4.  High-protein diet improves sensitivity to cholecystokinin and shifts the cecal microbiome without altering brain inflammation in diet-induced obesity in rats.

Authors:  Lixin Wang; Jonathan P Jacobs; Venu Lagishetty; Pu-Qing Yuan; Shuping V Wu; Mulugeta Million; Joseph R Reeve; Joseph R Pisegna; Yvette Taché
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-07-19       Impact factor: 3.619

5.  Antibiotics-mediated intestinal microbiome perturbation aggravates tacrolimus-induced glucose disorders in mice.

Authors:  Yuqiu Han; Xiangyang Jiang; Qi Ling; Li Wu; Pin Wu; Ruiqi Tang; Xiaowei Xu; Meifang Yang; Lijiang Zhang; Weiwei Zhu; Baohong Wang; Lanjuan Li
Journal:  Front Med       Date:  2019-05-02       Impact factor: 4.592

Review 6.  Update on the treatment of type 2 diabetes mellitus.

Authors:  Juan José Marín-Peñalver; Iciar Martín-Timón; Cristina Sevillano-Collantes; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2016-09-15

7.  Adaptation of Akkermansia muciniphila to the Oxic-Anoxic Interface of the Mucus Layer.

Authors:  Janneke P Ouwerkerk; Kees C H van der Ark; Mark Davids; Nico J Claassens; Teresa Robert Finestra; Willem M de Vos; Clara Belzer
Journal:  Appl Environ Microbiol       Date:  2016-09-23       Impact factor: 4.792

Review 8.  Microbiota and metabolic diseases.

Authors:  Alessia Pascale; Nicoletta Marchesi; Cristina Marelli; Adriana Coppola; Livio Luzi; Stefano Govoni; Andrea Giustina; Carmine Gazzaruso
Journal:  Endocrine       Date:  2018-05-02       Impact factor: 3.633

9.  Metformin ameliorates hepatic steatosis and improves the induction of autophagy in HFD‑induced obese mice.

Authors:  Min Li; Antara Sharma; Chunyan Yin; Xinrui Tan; Yanfeng Xiao
Journal:  Mol Med Rep       Date:  2017-05-26       Impact factor: 2.952

Review 10.  Obesity-associated cancer risk: the role of intestinal microbiota in the etiology of the host proinflammatory state.

Authors:  Zora Djuric
Journal:  Transl Res       Date:  2016-07-28       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.